Otamixaban

Otamixaban
Identifiers
	IUPAC name methyl (2R,3R)-2-(3-carbamimidoylbenzyl)-3- {[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate;
CAS Number	193153-04-7;
PubChem CID	5496659;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C25H26N4O4
Molar mass	446.498 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Otamixaban (INN) is an inhibitor of Factor Xa,^[1] currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

References

↑ Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. PMID 17979700.

Template:WikiDoc Sources

[pmid17979700-1] Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. PMID 17979700.

[1]

Otamixaban

Overview

See also

References

Navigation menu

Identifiers


IUPAC name methyl (2R,3R)-2-(3-carbamimidoylbenzyl)-3- {[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate
CAS Number	193153-04-7
PubChem CID	5496659
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₅H₂₆N₄O₄
Molar mass	446.498 g/mol